RedHill Biopharma (RDHL) Research & Development (2012 - 2023)

RedHill Biopharma (RDHL) has 12 years of Research & Development data on file, last reported at $1.2 million in Q2 2023.

• Research & Development for Q2 2023 came in at $1.2 million, down 15.29% year-over-year; the trailing twelve-month figure through Jun 2023 was $5.1 million (down 68.71% YoY), and the FY2025 annual result was $2.0 million, up 27.39% from the prior year.
• Research & Development improved to $1.2 million in Q2 2023 per RDHL's latest filing, from $1.1 million in the prior quarter.
• Over five years, Research & Development peaked at $10.3 million in Q2 2021 and troughed at $1.1 million in Q1 2023.
• A 5-year average of $4.1 million and a median of $3.1 million in 2020 frame the typical range for Research & Development.
• The sharpest annual moves came in 2021 and 2022: Research & Development soared 221.34% in 2021, then tumbled 85.75% in 2022.
• A 5-year view of Research & Development shows it stood at $2.3 million in 2019, then soared by 171.92% to $6.2 million in 2020, then fell by 5.19% to $5.9 million in 2021, then plunged by 80.69% to $1.1 million in 2022, then climbed by 10.06% to $1.2 million in 2023.
• Business Quant data shows RDHL's Research & Development at $1.2 million in Q2 2023, $1.1 million in Q1 2023, and $1.1 million in Q4 2022.